Ubs Group Ag Cognition Therapeutics Inc Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Cognition Therapeutics Inc stock. As of the latest transaction made, Ubs Group Ag holds 197,859 shares of CGTX stock, worth $87,057. This represents 0.0% of its overall portfolio holdings.

Number of Shares

197,859

Holding current value

$87,057

% of portfolio

0.0%

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$0.41 - $2.37 $81,122 - $468,925	197,859 New	197,859 $92,000
Q2 2023 Aug 11, 2023	BUY	$1.56 - $3.38 $951 - $2,061	610 New	610 $1,000
Q4 2022 Feb 08, 2023	BUY	$1.17 - $3.51 $2,758 - $8,276	2,358 Added 74.03%	5,543 $11,000
Q3 2022 Nov 10, 2022	BUY	$1.63 - $3.6 $3,726 - $8,229	2,286 Added 254.28%	3,185 $6,000
Q2 2022 Aug 10, 2022	SELL	$1.5 - $3.45 $4,275 - $9,832	-2,850 Reduced 76.02%	899 $2,000
Q4 2021 Feb 14, 2022	BUY	$5.1 - $12.98 $19,119 - $48,662	3,749 New	3,749 $24,000

Others Institutions Holding CGTX

# of Institutions

Shares Held

6.52M

Call Options Held

Put Options Held

View Full List

About COGNITION THERAPEUTICS INC

Ticker CGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,710,700
Market Cap $9.99M
Description
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical tr...

More about CGTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account